ANDA 91178, held by Genbiopro. Mifepristone.
As of Nov 16, 2026, ANDA 91178 (Mifepristone), held by Genbiopro, was first approved by FDA on Apr 11, 2019, with 4 approved supplements and 0 published complete response letters.
Mifepristone tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 11, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mifepristone200MG · tablet;oral | Mifepristone | Rx |
| Sep 30, 2025 | Supplement 7REMS | Approved | |
| Mar 23, 2023 | Supplement 6REMS | Approved | |
| Jan 3, 2023 | Supplement 4REMS | Approved | |
| May 14, 2021 | Supplement 3REMS | Approved | None posted |
| Apr 11, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters